Literature DB >> 31218513

Evaluation and Management of Elevated Blood Pressure in Children and Adolescents with Attention Deficit Hyperactivity Disorder.

Ikuyo Yamaguchi1, Coral Hanevold2.   

Abstract

PURPOSE OF REVIEW: To understand the impact of attention deficit hyperactivity disorder (ADHD) and its medications on blood pressure (BP) in children and adolescents and provide recommendations for management of elevated BP in children and adolescents with ADHD. RECENT
FINDINGS: ADHD medications have cardiovascular effects including elevated BP. However, the bulk of the evidence indicates that stimulants and other ADHD medications are safe and do not cause severe cardiovascular diseases. BP should be assessed carefully at the time of ADHD diagnosis, because some behavioral changes similar to ADHD may be associated with hypertension. ADHD medications appear to be safe. However, their long-term impact on the cardiovascular system is not clearly understood and needs further investigation. BP should be monitored regularly during ADHD pharmacotherapy in order to optimize the management of both conditions.

Entities:  

Keywords:  ADHD; Cardiovascular disease; Elevated blood pressure; Pediatric hypertension; Stimulants

Mesh:

Substances:

Year:  2019        PMID: 31218513     DOI: 10.1007/s11906-019-0968-1

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  57 in total

1.  The worldwide prevalence of ADHD: is it an American condition?

Authors:  Stephen V Faraone; Joseph Sergeant; Christopher Gillberg; Joseph Biederman
Journal:  World Psychiatry       Date:  2003-06       Impact factor: 49.548

2.  Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial.

Authors:  Joshua A Samuels; Kathy Franco; Fiona Wan; Jonathan M Sorof
Journal:  Pediatr Nephrol       Date:  2005-10-28       Impact factor: 3.714

3.  The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder.

Authors:  Russell A Barkley; Mariellen Fischer; Lori Smallish; Kenneth Fletcher
Journal:  J Abnorm Psychol       Date:  2002-05

Review 4.  The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies.

Authors:  Stephen V Faraone; Joseph Biederman; Eric Mick
Journal:  Psychol Med       Date:  2006-02       Impact factor: 7.723

5.  Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children.

Authors:  Tanya E Froehlich; Bruce P Lanphear; Jeffery N Epstein; William J Barbaresi; Slavica K Katusic; Robert S Kahn
Journal:  Arch Pediatr Adolesc Med       Date:  2007-09

6.  Inattention, hyperactivity, and school performance in a population of school-age children with complex congenital heart disease.

Authors:  Amanda J Shillingford; Marianne M Glanzman; Richard F Ittenbach; Robert R Clancy; J William Gaynor; Gil Wernovsky
Journal:  Pediatrics       Date:  2008-04       Impact factor: 7.124

Review 7.  Cardiovascular effects of atomoxetine in children, adolescents, and adults.

Authors:  Joachim F Wernicke; Douglas Faries; Donald Girod; Jeffrey Brown; Haitao Gao; Douglas Kelsey; Humberto Quintana; Robert Lipetz; David Michelson; John Heiligenstein
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

8.  Two cases of pheochromocytoma presenting with ADHD (attention deficit hyperactivity disorder)-like symptoms.

Authors:  Robert Haws; Mark Joseph; Raymond Adelman
Journal:  Pediatr Nephrol       Date:  2007-11-01       Impact factor: 3.714

9.  24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy.

Authors:  Cindy D Stowe; Stephanie F Gardner; Charles C Gist; Eldon G Schulz; Thomas G Wells
Journal:  Ann Pharmacother       Date:  2002 Jul-Aug       Impact factor: 3.154

10.  Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Almut G Winterstein; Tobias Gerhard; Jonathan Shuster; Michael Johnson; Julie M Zito; Arwa Saidi
Journal:  Pediatrics       Date:  2007-12       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.